cervical cancer

5 Cancer Vaccines to Watch in 2024
5 Cancer Vaccines to Watch in 2024
BioSpace
Merck
Moderna Therapeutics
melanoma
BioNTech
pancreatic cancer
OSE Immunotherapeutics
Transgene
non-small cell lung cancer
Nykode Therapeutics
cervical cancer
Flag link:
ESMO: Seagen and Genmab's Tivdak keeps cervical cancer patients alive longer
ESMO: Seagen and Genmab's Tivdak keeps cervical cancer patients alive longer
Fierce Pharma
ESMO
Pfizer
Seagen
cervical cancer
antibody-drug conjugate
Flag link:
Cervical cancer could be diagnosed earlier with new DNA biosensor
Cervical cancer could be diagnosed earlier with new DNA biosensor
Biopharma Reporter
cervical cancer
DNA
diagnostics
DNA biosensors
Flag link:
Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag
Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag
Yahoo/Zacks.com
Merck
Keytruda
FDA
cervical cancer
priority review
Flag link:
Genmab and Seagen’s TIVDAK trial meets primary endpoint
Genmab and Seagen’s TIVDAK trial meets primary endpoint
Clinical Trials Arena
Genmab
Seagen
Tivdak
clinical trials
cervical cancer
Flag link:
Phase III Data Show Keytruda’s Promise in Earlier-Stage Cervical Cancer
Phase III Data Show Keytruda’s Promise in Earlier-Stage Cervical Cancer
BioSpace
Merck
Keytruda
clinical trials
cervical cancer
Flag link:
AstraZeneca study points to new uses for targeted cancer drug Enhertu
AstraZeneca study points to new uses for targeted cancer drug Enhertu
BioPharma Dive
ASCO 2023
AstraZeneca
Enhertu
uterine cancer
cervical cancer
ovarian cancer
bladder cancer
Flag link:
Nykode collaborates with Roche for an upcoming trial in cervical cancer
Nykode collaborates with Roche for an upcoming trial in cervical cancer
Clinical Trials Arena
Nykode Therapeutics
Roche
cervical cancer
VB10.16
clinical trials
Flag link:
ASCO: Merck gives final look at Keytruda study in first-line cervical cancer. Will FDA change its mind?
ASCO: Merck gives final look at Keytruda study in first-line cervical cancer. Will FDA change its mind?
Fierce Pharma
ASCO 2023
Merck
Keytruda
cervical cancer
Flag link:
Nykode vaccine shows its worth in cervical cancer trial
Nykode vaccine shows its worth in cervical cancer trial
Pharmaforum
Nykode Therapeutics
vaccines
cervical cancer
VB10.16
Flag link:
AstraZeneca's Imfinzi Fails to Boost Survival in Cervical Cancer
AstraZeneca's Imfinzi Fails to Boost Survival in Cervical Cancer
BioSpace
AstraZeneca
Imfinizi
cervical cancer
clinical trials
Flag link:
Regeneron and Sanofi pull Libtayo app in cervical cancer, citing post-market study disagreement with FDA
Regeneron and Sanofi pull Libtayo app in cervical cancer, citing post-market study disagreement with FDA
Endpoints
Sanofi
Regeneron
Libtayo
cervical cancer
post-marketing studies
Flag link:
Immuno-oncology spotlight falls on cervical cancer
Immuno-oncology spotlight falls on cervical cancer
EP Vantage
immuno-oncology
cervical cancer
Opdivo
Keytruda
Bristol Myers Squibb
Merck
Flag link:
HPV vaccines reduce cervical cancer by 87%: study
HPV vaccines reduce cervical cancer by 87%: study
Biopharma Reporter
HPV
vaccines
cervical cancer
RWE
Flag link:
Agenus withdraws cervical cancer application, and a behind the scenes David vs. Big Pharma regulatory battle is revealed
Agenus withdraws cervical cancer application, and a behind the scenes David vs. Big Pharma regulatory battle is revealed
Fierce Biotech
Agenus
cervical cancer
balstilimab
Merck
Flag link:
Merck carves out path in first-line advanced cervical cancer with new FDA win for Keytruda juggernaut
Merck carves out path in first-line advanced cervical cancer with new FDA win for Keytruda juggernaut
Endpoints
Merck
Keytruda
FDA
cervical cancer
Flag link:
Regeneron Could Have a Big Catalyst Coming in 2022
Regeneron Could Have a Big Catalyst Coming in 2022
Motley Fool
Regeneron
Libtayo
cervical cancer
FDA
Sanofi
Flag link:
FDA hands accelerated nod to Seagen, Genmab's solo ADC in cervical cancer, but combo studies look even more promising
FDA hands accelerated nod to Seagen, Genmab's solo ADC in cervical cancer, but combo studies look even more promising
Endpoints
Seagen
Genmab
Tivdak
FDA
accelerated approval
cervical cancer
Flag link:
Merck fleshes out Keytruda win in first-line cervical cancer, adding more firepower to its early cancer push
Merck fleshes out Keytruda win in first-line cervical cancer, adding more firepower to its early cancer push
Endpoints
ESMO
Merck
Keytruda
Roche
Avastin
cervical cancer
Flag link:
Agenus, with FDA approval in sight, showcases anti-PD-1 data
Agenus, with FDA approval in sight, showcases anti-PD-1 data
Fierce Biotech
Agenus
FDA
balstilimab
cervical cancer
clinical trials
Flag link:

Pages